Compare REX AI Equity Premium Income ETF (AIPI) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Biogen Inc — how do they compare? REX AI Equity Premium Income ETF trades at $37.45, while Biogen Inc trades at $204.1 (market cap $30.13B). The key difference: Biogen Inc is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AIPI | BIIB | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $216.63 |
52-Week Low | $32.45 | $128.93 |
Market Cap | — | $30.13B |
Enterprise Value | — | $37.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.42, up 0.21% on the day, with a bullish technical signal from moving averages but bearish oscillators. The stock exhibits a high distribution yield strategy, paying weekly dividends, with recent payouts ranging from $0.23 to $0.26. Support and resistance are tightly clustered around $37-$38, indicating potential volatility. Recent news highlights the fund's transition to weekly distributions and questions about sustainability amid AI market dynamics.
The outlook for AIPI hinges on its ability to sustain high yields through its option-writing strategy, though structural risks and NAV erosion concerns persist. Investment opportunity lies in income generation, but risks include dependency on AI sector performance and capped upside. Analyst sentiment is mixed, with some caution over long-term viability.
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
